Novartis Pharma AG: Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%

AI Briefing

• – Novartis IgAN treatment shows promising results in slowing kidney function decline and reducing protein in urine.
• – Fabhalta lowers the likelihood of progression to kidney failure by 43% in the APPLAUSE-IgAN study.
• – Fabhalta demonstrates sustained reduction of protein in urine in 140.7% of patients over two years.